Prevalence of herpesvirus DNA in MS patients and healthy blood donors

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.

Download / Buy Article:

Abstract:

Objectives – The aim of this study is to determine the DNA prevalence of different members of Herpesviridae in multiple sclerosis (MS) patients and to describe the possible effect of β-interferon treatment on such prevalence. Material and methods – With a nested polymerase chain reaction (PCR) assay we have studied the DNA of the peripheral blood mononuclear cells (PBMCs) of 204 whole blood samples, [102 from patients with relapsing-remitting MS (RRMS), of which 62 were treated with β-interferon, and 102 from healthy blood donors]. Results – We only found a statistically significant difference for human herpesvirus type 6 (HHV-6) DNA prevalence (P < 0.0001): HHV-6 is 2.26 times more frequent in MS patients than in healthy donors. There was no difference in the HHV-6 prevalence between β-interferon treated and untreated patients. Conclusion – 1. Among the herpesviruses, HHV-6 was the only one showing altered prevalence. This either indicates that HHV-6 is involved in the pathogenesis of MS, or it simply indicates that MS influences latency or reactivation of HHV-6 without any direct involvement of HHV-6 in the disease process of MS. 2. Treatment with β-interferon does not make a difference on the DNA prevalence of the herpesviruses studied in our MS patients.

Keywords: -interferon; HHV-6; multiple sclerosis; nested PCR

Document Type: Original Article

Affiliations: 1: Clinical Microbiology Service, Hospital Clínico San Carlos, Madrid, Spain, 2: Neurology Service, Hospital Clínico San Carlos, Madrid, Spain, 3: Neurology Service, Hospital Clínico San Carlos, Madrid, Spain

Publication date: February 1, 2002

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more